Pharmos(PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: wolfdog2 who wrote (1256)	9/18/1998 9:40:00 AM
From: yosi s	Read Replies (1) of 1491

Revenues are going to be down in Q3 only because they were artificially high in the prior Q. You are lookng at PARs in a static fashion while it is changing direction. PARS has a certain burn rate, or fix expenses, that is inelastic. mostly R&D. On the revenues side. they got 2 Medication, and here they just started. so beforethey reach steady state they got to fill the pipeline once that is stable then Q to Q is relevent. Prior quater sales due to build in inventory. Now you got to make sale to replenish inventory. Rx rate and growh of Rx and new prescriber are better way to follow.( As is done by BOL and it is very promising) The problem here is that PARS got a big PR problem, their businss MODEL is GREAT but it is not very common, and as such they are not being compared properly. I do hope that just like the market underesimate PARS in 2-3 yrs they wll overestimate it. And if that happened the stock price will reflect a huge premium multiple ... I guess that is part of the business cycle.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next